1. Bauernfeind, A, Horl, G. Novel R-factor borne β-lactamase of Escherichia coli conferring resistance to cephalosporins. Infection 1987; 15: 257–259.
2. Hirakata, Y, et al. Regional variation in the prevalence of extended-spectrum β-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998–2002). Diagnostic Microbiology and Infectious Disease 2005; 52: 323–329.
3. Knothe, H, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315–317.
4. Bush, K. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clinical Infectious Diseases 2001; 32: 1085–1089.
5. Pfaller, MA, Segreti, J. Overview of the epidemiological profile and laboratory detection of extended-spectrum β-lactamases. Clinical Infectious Diseases 2006; 42 (Suppl. 4): S153–S163.
6. Wu, TL, et al. Dissemination of extended-spectrum β-lactamase-producing Enterobacteriaceae in intensive care units of a medical center in Taiwan. Microbial Drug Resistance 2006; 12: 203–209.
7. Yu, WL, Chuang, YC, Walther-Rasmussen, J. Extended-spectrum β-lactamases in Taiwan: epidemiology, detection, treatment and infection control. Journal of Microbiology, Immunology, and Infection 2006; 39: 264–277.
8. Garner, JS, et al. CDC definitions for nosocomial infections, 1988. American Journal of Infection Control 1988; 16: 128–140.
9. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 15th informational supplement M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA, 2005.
10. Su, LH, et al. Molecular investigation of two clusters of hospital-acquired bacteraemia caused by multi-resistant Klebsiella pneumoniae using pulsed-field gel electrophoresis and infrequent restriction site PCR. Journal of Hospital Infection 2000; 46: 110–117.
11. Chia, JH, et al. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M β-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan. Journal of Clinical Microbiology 2005; 43: 4486–4491.
12. Mabilat, C, Goussard, S. PCR detection and identification of genes for extended-spectrum β-lactamases. In: Persing, DH, Smith, TF, Tenover, FC, White, TJ, eds. Diagnostic Molecular Microbiology: Principle and Applications. Washington DC: American Society for Microbiology, 1993, pp. 553–559.
13. Rasheed, JK, et al. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrobial Agents and Chemotherapy 1997; 41: 647–653.
14. Ma, L, et al. CTX-M-14, a plasmid-mediated CTX-M type extended-spectrum β-lactamase isolated from Escherichia coli. Antimicrobial Agents and Chemotherapy 2002; 46: 1985–1988.
15. Pitout, JD, Hossain, A, Hanson, ND. Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp. Journal of Clinical Microbiology 2004; 42: 5715–5721.
16. Jean, SS, et al. Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. European Journal of Clinical Microbiology and Infectious Diseases 2009; 28: 215–220.
17. Rossi, F, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Journal of Antimicrobial Chemotherapy 2006; 58: 205–210.
18. Paterson, DL, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). Journal of Antimicrobial Chemotherapy 2005; 55: 965–973.
19. Ko, KS, et al. Prevalence and characterization of extended-spectrum β-lactamase-producing Enterobacteriaceae isolated in Korean hospitals. Diagnostic Microbiology and Infectious Disease 2008; 61: 453–459.
20. Hsueh, PR, Chen, WH, Luh, KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991–2003 at a university hospital in Taiwan. International Journal of Antimicrobial Agents 2005; 26: 463–472.
21. Livermore, DM. Defining an extended-spectrum β-lactamase. Clinical Microbiology and Infection 2008; 14 (Suppl. 1): 3–10.
22. Livermore, DM, et al. CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy 2007; 59: 165–174.
23. Bush, K. Extended-spectrum β-lactamases in North America, 1987–2006. Clinical Microbiology and Infection 2008; 14 (Suppl. 1): 134–143.
24. Kiratisin, P, et al. Molecular characterization and epidemiology of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic. Antimicrobial Agents and Chemotherapy 2008; 52: 2818–2824.
25. Karim, A, et al. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiology Letters 2001; 201: 237–241.
26. Woodford, N, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. Journal of Antimicrobial Chemotherapy 2004; 54: 735–743.
27. Gonullu, N, et al. Dissemination of CTX-M-15 β-lactamase genes carried on Inc FI and FII plasmids among clinical isolates of Escherichia coli in a university hospital in Istanbul, Turkey. Journal of Clinical Microbiology 2008; 46: 1110–1112.
28. Ma, L, et al. Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 2009; 53: 104–111.
29. Navon-Venezia, S, et al. Dissemination of the CTX-M-25 family β-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel. Journal of Antimicrobial Chemotherapy 2008; 62: 289–295.
30. Zong, Z, et al. Dominance of bla CTX-M within an Australian extended-spectrum β-lactamase gene pool. Antimicrobial Agents and Chemotherapy 2008; 52: 4198–4202.
31. Liu, SY, et al. Characterisation of plasmids encoding CTX-M-3 extended-spectrum β-lactamase from Enterobacteriaceae isolated at a university hospital in Taiwan. International Journal of Antimicrobial Agents 2007; 29: 440–445.
32. Coque, TM, Baquero, F, Canton, R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance 2008; 13(47).
33. Lewis, JS 2nd, et al. First report of the emergence of CTX-M-type extended-spectrum β-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrobial Agents and Chemotherapy 2007; 51: 4015–4021.
34. Zhanel, GG, et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005–2006. Antimicrobial Agents and Chemotherapy 2008; 52: 1430–1437.
35. Hawkey, PM. Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clinical Microbiology and Infection 2008; 14 (Suppl. 1): 159–165.
36. Yu, WL, et al. Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 β-lactamase in Taiwan. Antimicrobial Agents and Chemotherapy 2004; 48: 362–363.
37. Pitout, JD, et al. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrobial Agents and Chemotherapy 2007; 51: 1281–1286.
38. Lau, SH, et al. UK epidemic Escherichia coli strains A-E, with CTX-M-15 β-lactamase, all belong to the international O25:H4-ST131 clone. Journal of Antimicrobial Chemotherapy 2008; 62: 1241–1244.
39. Nicolas-Chanoine, MH, et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. Journal of Antimicrobial Chemotherapy 2008; 61: 273–281.
40. Suzuki, S, et al. Change in the prevalence of extended-spectrum β-lactamase producing Escherichia coli in Japan by clonal spread. Journal of Antimicrobial Chemotherapy 2009; 63: 72–79.
41. Mazzariol, A, et al. Detection of a new SHV-type extended-spectrum β-lactamase, SHV-31, in a Klebsiella pneumoniae strain causing a large nosocomial outbreak in the Netherlands. Antimicrobial Agents and Chemotherapy 2007; 51: 1082–1084.
42. Romero, ED, et al. Prevalence of clinical isolates of Escherichia coli and Klebsiella spp. producing multiple extended-spectrum β-lactamases. Diagnostic Microbiology and Infectious Disease 2007; 59: 433–437.
43. Liu, JH, et al. Detection and characterisation of CTX-M and CMY-2 β-lactamases among Escherichia coli isolates from farm animals in Guangdong Province of China. International Journal of Antimicrobial Agents 2007; 29: 576–581.
44. Mohamed Al-Agamy, MH, El-Din Ashour, MS, Wiegand, I. First description of CTX-M β-lactamase-producing clinical Escherichia coli isolates from Egypt. International Journal of Antimicrobial Agents 2006; 27: 545–548.